GGrantIndex
← Search

Planning & Evaluation

$57,648P30FY2018CANIH

Oregon Health & Science University, Portland OR

Investigators

Linked publications, trials & patents

Paper 39764100Paper 39763867Paper 39605535Paper 39435649Paper 39386578Paper 39375962Trial NCT07434128Trial NCT07278440Trial NCT07089940Trial NCT05705492Trial NCT04247425Trial NCT04172493Trial NCT04104139Trial NCT04061980Trial NCT04005690Trial NCT03961672Trial NCT03960177Trial NCT03699995Trial NCT03677531Trial NCT03649880Trial NCT03626285Trial NCT03613259Trial NCT03544125Trial NCT03479268Trial NCT03418025Trial NCT03406013Trial NCT03361436Trial NCT03347617Trial NCT03325166Trial NCT03280277Trial NCT03270059Trial NCT03261180Trial NCT03234309Trial NCT03135782Trial NCT03097588Trial NCT03028935Trial NCT03010358Trial NCT03009201Trial NCT02890979Trial NCT02869412Trial NCT02857218Trial NCT02779283Trial NCT02736617Trial NCT02522715Trial NCT02504359Trial NCT02503358Trial NCT02501759Trial NCT02498951Trial NCT02427841Trial NCT02359097Trial NCT02355262Trial NCT02312557Trial NCT02228265Trial NCT02100189Trial NCT02099864Trial NCT02092324Trial NCT02070705Trial NCT02050919Trial NCT01913015Trial NCT01748942Trial NCT01689987Trial NCT01649505Trial NCT01635413Trial NCT01620216Trial NCT01532687Trial NCT01498978Trial NCT01441882Trial NCT01422408Trial NCT01253642Trial NCT01031953Trial NCT01005914Trial NCT00983398Trial NCT00978562Trial NCT00900302Trial NCT00900068Trial NCT00900055Trial NCT00899795Trial NCT00899522Trial NCT00843167Trial NCT00822848Trial NCT00764517Trial NCT00722072Trial NCT00691652Trial NCT00662103Trial NCT00660543Trial NCT00659126Trial NCT00627276Trial NCT00516542Trial NCT00482274Trial NCT00425386Trial NCT00324324Trial NCT00303849Trial NCT00293475Trial NCT00253721Trial NCT00253643Trial NCT00238433Trial NCT00227682Trial NCT00103038Trial NCT00075387Patent 9279811

Abstract

Planning and Evaluation ABSTRACT Under the leadership of the Director, Brian Druker, rigorous planning and evaluation efforts continue to be a critical activity, focused on the ongoing growth and development of the OHSU Knight Cancer Institute (Knight). Druker shares the responsibility for establishing the vision and strategic plans with the Knight Senior Leadership composed of Tomasz Beer, M.D. (Deputy Director and Interim Associate Director Clinical Research), Lisa Coussens, Ph.D. (Associate Director Basic Research), Sara Courtneidge, Ph.D. (Associate Director Translational Research), Joe Gray, Ph.D. (Associate Director Biophysical Oncology), Ray Bergan, M.D. (Associate Director Medical Oncology), Kristin Bialobok, M.S.N (Associate Director Administration), and Mary Stenzel-Poore, Ph.D. (School of Medicine Associate Dean, Research). This group, together with external advisors, undertook extensive strategic planning and evaluation efforts with the goal of enhancing the productivity of our center. Three committees are responsible for the internal governance of the Knight: the Associate Directors Advisory Group, the Program Leaders and Shared Resource Directors Committee, and the Clinical Executive Group. These committees are structured to ensure successful operation of the Knight, support new initiatives and to promote interactions within and between programmatic elements of the Knight. The External Advisory Board (EAB) is a distinguished group of cancer specialists and is chaired by Dr. Joseph Simone. The EAB reviews the Knight's scientific progress, vision, and future plans. Further ad hoc discussions may occur between the Director and EAB members throughout the year. The EAB reviews the organizational structure, programs, and shared resources providing advice regarding whether each is adding value to the institute's mission. They evaluate scientific excellence, focus, and interactivity of each program. The EAB provides formal reports to the Director, which are shared with the OHSU President and Dean of the SOM. The recommendations of this group have been essential in developing our current leadership and program structure, and shared resources. The EAB has consistently helped us develop a programmatic structure that optimally aligns with the strengths of our institute, optimizes the capacity of programs to create trans-disciplinary studies, and supports inter-programmatic interactions. To engage the Knight membership in strategic planning, and to stimulate intra- and inter-programmatic member interactions, routine programmatic meetings, as well as a number of Knight-wide and programmatic retreats were held. Development Funds, in the form of pilot project awards, were provided to stimulate collaborative publications and multi-investigator grants. This investment and planning has successfully resulted in an overall member collaborative publication rate of 39%, as well as a significant increase in multi-investigator grants.

View original record on NIH RePORTER →